Skip to main content

Table 1 Characteristics and p-value of patients that have PSA after nadir

From: Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy

  Total CRPC p-value
Number of patients 261 96 -
Mean follow-up ± s.d. 38.7 ± 3.5 15.8 ± 2.4 -
Mean age ± s.d. 74 ± 0.9 75.2 ± 1.7 0.011
Mean time to nadir ± s.d. 10.3 ± 1.3 8.9 ± 1.9 0.001
Mean pretreatment PSA ± s.d. 119.4 ± 39.4 151.5 ± 80.3 0.054
Mean PSA nadir ± s.d. 12.8 ± 11.7 6.6 ± 4.2 0.142
Bone metastasis    
Yes 41 15 0.490
No 220 79  
Gleason score    0.117
≤ 6 59 (22.6 %) 20 (21.2 %)  
7 72 (27.5 %) 21 (22.3 %)  
≥ 8 130 (49.8 %) 53 (56.3 %)  
ADT type    
Leuprin only 154 44 0.012
Zoladex only 36 10  
Leuprin → Zoladex 9 6  
Zoladex → Leuprin 49 27  
Anti-androgen only 13 7